Lytix Biopharma AS (OSL:LYTIX)

Market Cap	717.84M +82.6%
Revenue (ttm)	377.00K -96.5%
Net Income	-73.23M
EPS	-1.07
Shares Out	75.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,328
Average Volume	68,291
Open	9.60
Previous Close	9.56
Day's Range	9.52 - 9.60
52-Week Range	4.55 - 11.90
Beta	-0.44
RSI	55.45
Earnings Date	Feb 12, 2026

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 7
• Stock Exchange: Oslo Børs
• Ticker Symbol: LYTIX

Financial Performance

In 2024, Lytix Biopharma AS's revenue was 11.13 million, an increase of 178.98% compared to the previous year's 3.99 million. Losses were -94.27 million, 7.24% more than in 2023.